

**Qizhi Tang** is a professor of immunology in the Diabetes Center, the Department of Surgery, the Gladstone Institute of Genomic Immunology, and the Institute of Regenerative Medicine at the University of California, San Francisco (UCSF). One area of research focus in the Tang Lab is on investigating regulatory T cell control of autoimmune diabetes and transplant rejection and translating insights from basic mechanistic research to novel therapies. In the past 10 years, she has led translational efforts to design and implement 10 Treg-based clinical trials in autoimmune diseases and organ transplantation. Currently, pre-clinical research in her lab focuses on developing cellular engineering strategies to enhance human Treg potency and lineage stability. Another area of research in the Tang lab is to optimize beta cell replacement therapy for type 1 diabetes by improving islet survival in ischemia and designing strategies to avoid immune rejection without systemic immunosuppression